Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Renal Outer Medullary Potassium Channel (ROMK), encoded by the KCNJ1 gene, is an inwardly rectifying potassium channel primarily expressed in the kidney. It plays a crucial role in potassium secretion and recycling within the nephron, contributing to overall potassium homeostasis. ROMK is a target for novel diuretics and antihypertensive drugs that aim to avoid hypokalemia. Dysfunction of ROMK is associated with Bartter syndrome type II and hypertension. It has also been identified as a component of mitochondrial ATP-sensitive K+ channels involved in cardioprotection during ischemia-reperfusion injury and neuroprotection during hypoxia/stroke events.
Selective inhibition of ROMK to modulate renal salt handling without excessive potassium loss.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Renal Outer Medullary Potassium Channel (ROMK).